-+ 0.00%
-+ 0.00%
-+ 0.00%

BioXcel Therapeutics wins court approval for bankruptcy asset sale to Teva

PUBT·10/30/2026 21:16:19
Listen to the news
BioXcel Therapeutics wins court approval for bankruptcy asset sale to Teva
  • A bankruptcy court cleared BioXcel Therapeutics' asset sale to Teva Pharmaceuticals International, allowing the transaction to close immediately.
  • Consideration includes a $57.5 million upfront payment, subject to adjustments, with additional payments contingent on development and commercial milestones.
  • Teva will assume specified liabilities, with its contract cure-cost obligation capped at $2.5 million.
  • The assets will transfer free of liens and claims, except permitted encumbrances and assumed liabilities.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioXcel Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-120737), on October 30, 2026, and is solely responsible for the information contained therein.